Dr Reddy’s, Prestige BioPharma partner to commercialise Trastuzumab biosimilar for cancer treatment
Hyderabad: Hyderabad-based Dr Reddy’s Laboratories and Prestige BioPharma have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia. Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin and can be prescribed for the […]
Hyderabad: Hyderabad-based Dr Reddy’s Laboratories and Prestige BioPharma have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia.
Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer.
Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is overexpressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.
The license agreement grants Dr Reddy’s the exclusive rights to commercialise the proposed biosimilar in select countries in Latin America and Southeast Asia.
Under this partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr Reddy’s will be responsible for local registrations, marketing and sales in the licensed territories.
Lisa S Park, CEO of Prestige BioPharma, said, “Dr Reddy’s is the ideal partner to commercialise our lead biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets.”
MV Ramana, CEO, Branded Markets (India & Emerging Markets), Dr Reddy’s, added, the partnership with Prestige BioPharma will help both the companies combine established expertise in the biosimilars with the commercial strengths and growth ambition in these markets.
“This is in line with our stated intention to create a portfolio of oncology products and expand our biosimilar offerings in emerging markets,” Ramana added.
Now you can get handpicked stories from Telangana Today on Telegram everyday.
Click the link to subscribe. Click to follow Telangana Today Facebook page and Twitter .
